Contributions
Abstract: EP1541
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background: Functional MRI (fMRI) provides information about the plasticity of the human brain. Special interest has arisen from the study of cognitive impairment and Resting State (RS) fMRI in MS.
Objective: To investigate RS differences in MS patients with low level of motor disability with and without cognitive impairment and to correlate these findings with clinical and neuropsychological measures.
Methods: Cross-sectional study including RS fMRI and structural images (3D T1/FLAIR) acquired from a 3T scanner (Philips Ingenia). Clinical evaluations and a complete neuropsychological battery were also performed on the same day ± 2 weeks. Verbal Episodic Memory (VEM-California Verbal Learning Test VIII-CVLT) and Social Cognition (SOC-Mini Social and Emotional Assessment-miniSEA) were assessed creating groups (normalVEM vs. impairedVEM and normalSOC vs. impairedSOC) according to Z score with a cut-off ≤ -1.5. RS studies were analysed with MELODIC/FSL. After concatenating all studies, RS networks were visually identified. Then, a dual regression analysis was performed to assess the differences between normalVEM vs. impairedVEM, and normalSOC vs. impairedSOC. Finally, the mean value for each subject in the clusters that showed significant differences (p< 0.05 threshold free cluster enhancement images) was extracted to correlate with the clinical and neuropsychological measurements.
Results: We included 37 relapsing-remitting MS patients, 65% women, mean age 36.2 ± 9 years, mean disease duration 6.4 ± 4 years, median EDSS 1.0 (range 0 - 6). Verbal Episodic Memory was impaired in 45.9% and Social Cognition in 24.3%. RS showed significant differences (decreases and increases) in networks including sensory-motor, visual, executive, default network and cerebellum for both group comparisons. In addition, differences found in the VEM group comparison were correlated with CVLT Z score and EDSS (normalVEM median EDSS 1.0 vs. impairedVEM median EDSS 2.0, p=0.04); while differences found in the SOC group comparison, were correlated with miniSEA Z score. The direction and magnitude of the correlations were dependent on the region.
Conclusion: When MS patients were classified according to their VEM or SOC impairment, RS showed significant differences in brain synchronization. Interestingly, RS was sensitive to mild differences of EDSS in the VEM group. Results suggest that RS could reflect the cognitive status of MS patients within plausible neurocognitive networks.
Disclosure:
Ethel Ciampi has nothing to disclose
Tomás Labbe has nothing to disclose
Reinaldo Uribe-San-Martin has nothing to disclose
Juan Pablo Cruz has nothing to disclose
Macarena Vasquez has nothing to disclose
Ana Reyes reports has nothing to disclose
Claudia Cárcamo has nothing to disclose
Álex Rovira serves on scientific advisory boards for Novartis, Sanofi-Genzyme, and OLEA Medical, has received speaker honoraria from Bayer, Sanofi-Genzyme, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis and Biogen Idec, and has research agreements with Siemens AG and Icometrix.
Deborah Pareto has nothing to disclose
Abstract: EP1541
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background: Functional MRI (fMRI) provides information about the plasticity of the human brain. Special interest has arisen from the study of cognitive impairment and Resting State (RS) fMRI in MS.
Objective: To investigate RS differences in MS patients with low level of motor disability with and without cognitive impairment and to correlate these findings with clinical and neuropsychological measures.
Methods: Cross-sectional study including RS fMRI and structural images (3D T1/FLAIR) acquired from a 3T scanner (Philips Ingenia). Clinical evaluations and a complete neuropsychological battery were also performed on the same day ± 2 weeks. Verbal Episodic Memory (VEM-California Verbal Learning Test VIII-CVLT) and Social Cognition (SOC-Mini Social and Emotional Assessment-miniSEA) were assessed creating groups (normalVEM vs. impairedVEM and normalSOC vs. impairedSOC) according to Z score with a cut-off ≤ -1.5. RS studies were analysed with MELODIC/FSL. After concatenating all studies, RS networks were visually identified. Then, a dual regression analysis was performed to assess the differences between normalVEM vs. impairedVEM, and normalSOC vs. impairedSOC. Finally, the mean value for each subject in the clusters that showed significant differences (p< 0.05 threshold free cluster enhancement images) was extracted to correlate with the clinical and neuropsychological measurements.
Results: We included 37 relapsing-remitting MS patients, 65% women, mean age 36.2 ± 9 years, mean disease duration 6.4 ± 4 years, median EDSS 1.0 (range 0 - 6). Verbal Episodic Memory was impaired in 45.9% and Social Cognition in 24.3%. RS showed significant differences (decreases and increases) in networks including sensory-motor, visual, executive, default network and cerebellum for both group comparisons. In addition, differences found in the VEM group comparison were correlated with CVLT Z score and EDSS (normalVEM median EDSS 1.0 vs. impairedVEM median EDSS 2.0, p=0.04); while differences found in the SOC group comparison, were correlated with miniSEA Z score. The direction and magnitude of the correlations were dependent on the region.
Conclusion: When MS patients were classified according to their VEM or SOC impairment, RS showed significant differences in brain synchronization. Interestingly, RS was sensitive to mild differences of EDSS in the VEM group. Results suggest that RS could reflect the cognitive status of MS patients within plausible neurocognitive networks.
Disclosure:
Ethel Ciampi has nothing to disclose
Tomás Labbe has nothing to disclose
Reinaldo Uribe-San-Martin has nothing to disclose
Juan Pablo Cruz has nothing to disclose
Macarena Vasquez has nothing to disclose
Ana Reyes reports has nothing to disclose
Claudia Cárcamo has nothing to disclose
Álex Rovira serves on scientific advisory boards for Novartis, Sanofi-Genzyme, and OLEA Medical, has received speaker honoraria from Bayer, Sanofi-Genzyme, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis and Biogen Idec, and has research agreements with Siemens AG and Icometrix.
Deborah Pareto has nothing to disclose